Need a mesothelioma lawyer? We will fight for you!
› $150,000,000 verdict in personal injury case
The Ortho Evra birth control patch has updated the CONTRAINDICTATIONS, WARNINGS and ADVERSE REACTIONS sections on its label and packaging, according to the Food and Drug Administration’s MedWatch July 2009 Drug Safety Labeling Changes posting. Ortho Evra was one of 38 drugs listed in the report.
A new provision in the proposed budget signed by President Barack Obama last week could help significantly reduce the cost of birth control for young women by allowing pharmaceutical companies to reinstate discounts on contraceptives that they had previously offered to family planning clinics.
A British survey suggests one in three women spend no more than five minutes selecting a suitable contraceptive method to use, according to Medical News Today. The report, conducted by Family Planning Association, is part of the organization’s Finding the Perfect Partner (Choose What You Use) campaign to help reduce unplanned pregnancy and abortion, and to promote greater control over contraceptive choice among women and health professionals. It found that despite the seemingly little care women put into the decision of what type of birth control to use, nearly half have had an unwanted pregnancy scare.
Students at Texas Christian University (TCU) now have access to more affordable contraceptives through the university’s Health Center, according to the TCU news Web site Daily Skiff. The Health Center negotiated a contract with drug companies to offer the discounted rates to students requesting contraceptives such as Ortho Tri-Cyclen and the Ortho Evra Contraceptive Transdermal Patch.
Public Citizen, an 80,000-member nonprofit organization dedicated to consumer advocacy, petitioned the FDA to ban Johnson & Johnson’s contraceptive patch Ortho Evra (ethinyl estradiol/norelgestromin). The organization requested complete removal of the contraceptive within 6 months.
The FDA approved a label change to Johnson & Johnson’s Ortho Evra birth control patch on January 18, 2008. The patch has been known to cause blood clots which can lead to pulmonary embolism and death. The label change comes after testing revealed women on the patch between the ages of 15-44 are at a higher risk for pulmonary embolism.
Ortho Evra manufacturer, Johnson & Johnson, recently settled a lawsuit with the family of a 14-year-old girl killed by the defective birth control patch. The case is just one of many Ortho Evra lawsuits settled by Johnson & Johnson prior to going trial.
![[ Beasley Allen Law Firm Logo ]](http://www.orthoevra-legal.com/wp-content/themes/system-unity/images/logo.png){kind=logo}